BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113:31-44. [PMID: 25680808 DOI: 10.1093/bmb/ldv004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Sundaram V, Kowdley KV. Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepat Med 2016;8:75-80. [PMID: 27418860 DOI: 10.2147/HMER.S63125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. J Urban Health 2018;95:71-82. [PMID: 28875410 DOI: 10.1007/s11524-017-0185-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
3 Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, Sharma RK, Rai P, Aggarwal R. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton) 2019;24:316-21. [PMID: 29327401 DOI: 10.1111/nep.13222] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
4 Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2016;10:13-20. [PMID: 26560449 DOI: 10.1586/17474124.2016.1116937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339 [PMID: 26962399 DOI: 10.4254/wjh.v8.i6.331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Boodram B, Kaufmann M, Aronsohn A, Hamlish T, Peregrine Antalis E, Kim K, Wolf J, Rodriguez I, Millman AJ, Johnson D. Case Management and Capacity Building to Enhance Hepatitis C Treatment Uptake at Community Health Centers in a Large Urban Setting. Fam Community Health. 2020;43:150-160. [PMID: 32079971 DOI: 10.1097/fch.0000000000000253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee SS, Kilvert L, Liu H, Trepanier J. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study. Dig Liver Dis 2016;48:344. [PMID: 26459137 DOI: 10.1016/j.dld.2015.08.015] [Reference Citation Analysis]
8 Edwards DJ, Coppens DG, Prasad TL, Rook LA, Iyer JK. Access to hepatitis C medicines. Bull World Health Organ. 2015;93:799-805. [PMID: 26549908 DOI: 10.2471/blt.15.157784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
9 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
10 Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol 2017;88:46-51. [PMID: 28160728 DOI: 10.1016/j.jcv.2017.01.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
11 Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ. Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrob Agents Chemother 2015;59:7671-9. [PMID: 26416874 DOI: 10.1128/AAC.01693-15] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 2.9] [Reference Citation Analysis]
12 Refaat B, Ashshi AM, El-Shemi AG, Azhar E. Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm 2015;2015:287640. [PMID: 25969625 DOI: 10.1155/2015/287640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
13 Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D. Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med 2017;10:79-91. [PMID: 28405170 DOI: 10.2147/PGPM.S125452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Yee BE, Nguyen NH, Jin M, Lutchman G, Lim JK, Nguyen MH. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterol. 2016;3:e000056. [PMID: 26966547 DOI: 10.1136/bmjgast-2015-000056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
15 Falcão EM, Trope BM, Godinho MM, Carneiro LH, de Araujo-Neto JM, Nogueira CA, Ramos-E-Silva M. Cutaneous Eruption due to Telaprevir. Case Rep Dermatol 2015;7:253-62. [PMID: 26500538 DOI: 10.1159/000439264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Craxì L, Cammà C, Craxì A. HCV: the best cure possible or the best possible cure? J Viral Hepat 2015;22:627-9. [PMID: 26135025 DOI: 10.1111/jvh.12411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS One 2018;13:e0199874. [PMID: 29975764 DOI: 10.1371/journal.pone.0199874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Refaat B, El-Shemi AG, Ashshi AM, Mahamid EW, Al-Qadi NM. Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat. Mediators Inflamm 2015;2015:414207. [PMID: 26236109 DOI: 10.1155/2015/414207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100-2109 [PMID: 26301052 DOI: 10.4254/wjh.v7.i17.2100] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
21 Verma S, Ide K, Shimizu S, Das LK, Tahara H, Ohira M, Ishiyama K, Tanaka Y, Tashiro H, Ohdan H. Kidney transplantation from an anti-hepatitis C virus antibody-positive donor into an anti-hepatitis C virus antibody-negative recipient: A case report. Transplantation Reports 2016;1:4-6. [DOI: 10.1016/j.tpr.2016.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Indian J Gastroenterol 2017;36:227-34. [PMID: 28656492 DOI: 10.1007/s12664-017-0763-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lee SS, Williams SA, Pinto J, Israelson H, Liu H. Treating hepatitis C during the COVID-19 pandemic in Alberta. CanLivJ 2021;4:79-81. [DOI: 10.3138/canlivj-2021-0007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Vidal LL, Soares MA, Santos AF. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. J Viral Hepat 2016;23:840-9. [PMID: 26775769 DOI: 10.1111/jvh.12503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]